Patient Education · Menopause & Midlife Health

Perimenopause and Menopause: Symptoms, Brain Fog, and Evaluation

A common frustration in this transition is being told a hormone test was “normal.” In perimenopause, that result often means very little — and knowing why saves a lot of wasted testing.

Written . The position-statement quotation below is from the document named in the Sources list. Symptom description and evaluation are written as general clinical practice rather than from a single retrieved guideline. Editorial standards

Menopause has a precise definition and perimenopause does not, which is the source of most of the confusion around it.

The definitions, and why testing disappoints

Menopause is diagnosed looking backwards: it is the point twelve consecutive months after the final menstrual period. Perimenopause is the transition leading to it, and it is recognised from a pattern — changing cycle length, changing flow, and the appearance of symptoms — rather than from a number.

That is why hormone testing so often disappoints. During the transition, levels fluctuate substantially from cycle to cycle and even week to week. A single result drawn on one day can look entirely unremarkable in a woman whose cycles and sleep have plainly changed. Being told the test was normal is not evidence that nothing is happening; it usually means the test was the wrong instrument for the question.

Testing does have a role — particularly when menopause appears unusually early, when periods stop without explanation, or when thyroid disease, pregnancy or another cause needs excluding. The distinction is between testing to answer a specific question and testing in the hope of confirming a transition that is better recognised from the pattern.

The vocabulary, and why it keeps causing confusion

Several terms get used interchangeably and are not interchangeable. Perimenopause is the transition. Menopause is a single point in time, identified retrospectively twelve months after the final period. Postmenopause is everything after that point. Early menopause refers to menopause occurring earlier than usual; before 40 it is described as primary ovarian insufficiency and managed differently, which is covered in its own article.

The practical consequence is that “I’m in menopause” usually means “I’m in perimenopause”, and the distinction changes both the contraception question and the treatment question. Being precise about where you are is worth the pedantry.

What the transition actually looks like over time

The transition is not a steady decline. Cycle length typically becomes variable first, and for some women it shortens before it lengthens. Skipped periods tend to come later, and the gaps lengthen unevenly rather than progressively. A woman can go three months without a period and then have two in six weeks, and neither pattern means the transition has reversed.

Symptom intensity follows no fixed order either. Some women get vasomotor symptoms years before their cycles change; others have marked cycle change with almost no flushing. Duration varies widely between individuals, which is why any statement about how long this lasts is close to useless at the individual level.

Testing that does have a role

Hormone testing is unhelpful for confirming the transition itself, but several tests earn their place when the picture is not straightforward. A thyroid function test, because thyroid disease produces overlapping symptoms. A full blood count and ferritin where bleeding has been heavy. ACOG advises that serum ferritin be obtained routinely in women presenting with heavy menstrual bleeding, identifies iron deficiency by a ferritin below 15 micrograms/L, and notes that a normal or high ferritin does not rule it out because ferritin rises in inflammation — so a normal blood count alone does not settle the question. A pregnancy test where periods have stopped and contraception has been inconsistent.

Testing is also warranted where menopause appears early. Periods stopping unusually early is worth investigating rather than accepting; before 40 it is a different diagnosis, primary ovarian insufficiency, with different management — covered in its own article linked below. If your periods stopped in your thirties or early forties, that is a reason to ask specifically what was excluded.

Contraception has not ended

This is the most consequential practical point in the whole transition. Irregular cycles mean unpredictable ovulation, not absent ovulation. Pregnancy remains possible until menopause is established, . If you do not want to become pregnant, contraception continues to be a live question — and which method suits you may change, since some choices interact with bleeding patterns and with cardiovascular risk factors that become a more prominent consideration at this stage of life.

The symptom pattern

Beyond cycle change, the transition commonly brings hot flashes and night sweats, disrupted sleep, mood change or increased anxiety, joint aches, changes in skin and hair, altered weight distribution, and genitourinary symptoms including dryness and urinary urgency. Not everyone gets all of them, severity varies enormously, and the order is unpredictable.

On treatment for the vasomotor symptoms, the 2022 hormone therapy position statement of The North American Menopause Society states that hormone therapy “remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.” Whether it is right for a particular woman is a separate question involving timing, route and individual risk.

Sleep, and why it deserves separate attention

Sleep disruption in this period has separable causes that respond to different things. Night sweats wake you directly. Anxiety or a racing mind at 3am is a second mechanism. And a sleep disorder is a third.

One nuance is worth knowing because it is often stated the other way round. The evidence that self-reported sleep quality declines across the transition is strong — but polysomnographic studies have generally not found a corresponding negative change in sleep architecture, and some have found more slow-wave sleep in peri- and post-menopausal women. So the experience of worse sleep is real and well documented, while the mechanism is less settled than confident explanations suggest.

Sorting which is operating matters because the treatments diverge. If you are waking drenched, the vasomotor symptom is the target. If you are waking without sweats and then unable to return to sleep, treating hot flashes will not fix it, and a sleep-directed approach is the relevant one. Persistent snoring, witnessed pauses in breathing, or waking unrefreshed despite adequate hours point toward sleep apnoea.

Mood, and what should not be attributed to hormones

Mood change during the transition is common and is not simply a reaction to symptoms. The Study of Women’s Health Across the Nation found women two to four times more likely to develop major depressive disorder during the menopausal transition and early post-menopause than before it, after adjusting for confounding factors.

Risk is not evenly distributed. Women who have been vulnerable to mood symptoms during other reproductive transitions — premenstrually, or postpartum — are at greater risk of depressive symptoms during this one, and the presence of hot flashes is itself an independent risk factor. If any of that describes you, it is a reason to raise mood early rather than wait and see.

Two things should not be folded into “it’s hormonal” without assessment: a first episode of significant depression, and any thoughts of self-harm.

The practical marker is function rather than feeling. Low mood that lifts when circumstances improve is different from low mood that persists regardless, interferes with work or relationships, or comes with loss of interest in things that previously mattered. The second is a reason to be assessed on its own terms.

Brain fog

Difficulty concentrating, losing a word mid-sentence, walking into a room and forgetting why — these are among the most distressing symptoms of the transition, largely because of what women fear they mean. Cognitive complaints during this period are common, and they are not on their own a diagnosis of anything.

They also rarely occur alone. Broken sleep, night sweats waking you repeatedly, low mood, anxiety, and the sheer cognitive load of this life stage all degrade concentration independently, and they compound each other. Those are worth addressing on their own terms before concluding the fog is unexplained — not because one is known to work better than another, but because each is treatable and each is contributing.

What does deserve evaluation rather than reassurance: cognitive change that is progressive rather than fluctuating, that others notice more than you do, that interferes with familiar tasks, or that comes with new neurological symptoms.

Joint aches, palpitations, and the symptoms nobody warned you about

Several common transition symptoms are poorly publicised, which leads women to investigate them separately or to worry unnecessarily. Joint and muscle aches, particularly morning stiffness, are among them. So are palpitations, which are worth mentioning because they overlap with thyroid disease and with anxiety, and because palpitations with chest pain, breathlessness or fainting are not to be attributed to menopause without assessment.

Skin dryness and itching, changes in body odour, dry eyes, altered taste, and increased urinary frequency also occur. None of these needs treating simply because it appears, but knowing they belong to the same picture prevents a series of unconnected appointments.

Bleeding that needs evaluation

Irregularity is expected. These patterns are not, and should be assessed rather than attributed to the transition: bleeding that soaks through protection hourly or contains large clots; bleeding lasting substantially longer than your normal period; bleeding between periods; bleeding after intercourse; and any bleeding at all once twelve months have passed without one.

That last one matters most. Postmenopausal bleeding is never simply a late period.

What changes about long-term health

The transition is not only a symptom event. Bone health and cardiovascular risk both become more prominent considerations around this stage of life, which is why it is a sensible moment for a broader review rather than a symptom-only consultation. The 2022 menopause position statement is explicit that hormone therapy has been shown to prevent bone loss and fracture, which is one reason bone comes into the conversation here rather than later.

Concretely: blood pressure measured properly, a lipid profile, discussion of bone health including whether any risk factors for fracture apply, and confirmation that cervical and breast screening are up to date. None of that is urgent in the way a symptom is, but the transition is when it is most likely to be prompted.

Where this fits with the rest of your care

The transition intersects with several other things at once, and treating it in isolation is why some women end up with four appointments where one would have done. Contraception decisions change. Cervical and breast screening continue on their own schedules regardless of symptoms. Bone and cardiovascular risk enter the picture. And any pre-existing condition — migraine, thyroid disease, depression, diabetes — may behave differently through the transition and may alter which treatments are suitable.

The practical version: rather than booking about hot flashes, book about the transition, and bring the whole picture. It is a more efficient use of an appointment and it produces a plan rather than a prescription.

Work, and what reasonable adjustment looks like

Symptoms severe enough to affect work are often managed silently. The practical adjustments that help are unglamorous: control over temperature where possible, access to water and to a bathroom, flexibility around meetings when sleep has been badly broken, and uniform or dress-code latitude where synthetic fabrics make flushing worse.

Whether to disclose is a personal decision with no right answer. What is worth knowing is that symptoms affecting your ability to do your job are a health matter rather than a performance matter, and that framing them that way is worth doing, and a clinician is often the easier first conversation.

What partners and families often get wrong

Two misunderstandings do the most damage. The first is treating mood change as a personality shift rather than a symptom, which isolates the woman experiencing it. The second is the assumption that once symptoms are treated everything returns to how it was — when sleep debt, altered libido and changed body composition may all need addressing separately and over a longer period.

The useful thing a family member can do is specific rather than sympathetic: notice what has changed, say so without diagnosing it, and support the process of getting it assessed properly rather than waiting for it to pass.

A note on what is not yet settled

Two things are worth holding loosely. The relationship between the transition and long-term cognitive outcomes remains an active research question rather than a settled one, so confident claims in either direction — that the transition causes lasting cognitive decline, or that it certainly does not — run ahead of the evidence. And the optimal management of the transition itself, as distinct from established menopause, is less well studied than either the years before or the years after.

That uncertainty is a reason to reassess periodically rather than to decide once, and a reason to treat any source offering a definitive answer to those particular questions with some caution.

What to bring to a visit

  • A cycle record over three months — the start date of each period, how many days it lasted, and a rough marker of heaviness for the worst day
  • A count of hot flashes on a typical day, and the number of nights sleep was broken in a week
  • Which symptom is most disruptive, and what it stops you doing
  • Your sleep pattern, including whether night sweats wake you
  • Current contraception, if any
  • Blood pressure readings, and family history of heart disease, blood clots or breast cancer

Three months of that is more informative than any single hormone level, because it captures the variability that defines the transition. It also converts a consultation from description into evidence, which changes how the conversation goes.

Main takeaway

Perimenopause is recognised from the pattern, not from a hormone level, so a normal result does not settle the question. Contraception is still needed until menopause is established. Cognitive symptoms are common, and broken sleep, low mood and cognitive load each contribute independently — all are worth addressing before concluding the fog is unexplained. And bleeding that is very heavy, occurs between periods, or occurs after twelve months without one is evaluated rather than explained away.

Sources

  • The 2022 hormone therapy position statement of The North American Menopause Society Advisory Panel. Menopause. ;29(7):767–794. doi:10.1097/GME.0000000000002028 — full statement (PDF). Quoted here for the statement that hormone therapy “remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.”
  • Sleep and sleep disorders in the menopausal transition (), PMC6092036 — PMC full text. Cited by title and PMC identifier; authorship was not confirmed from the retrieved text and is not stated here. Source for: the Study of Women’s Health Across the Nation finding that women were two to four times more likely to develop major depressive disorder during the menopausal transition and early post-menopause than pre-menopause after adjustment; that women vulnerable to mood symptoms during other reproductive transitions are at greater risk during this one; and that while evidence for declining self-reported sleep quality is strong, polysomnographic studies have generally not found a corresponding negative change in sleep architecture.
  • Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding, ACOG Committee Opinion No. 785, ACOG. Cited here for the ferritin advice: that serum ferritin should be obtained routinely where menstrual bleeding has been heavy, that iron deficiency is identified by a ferritin below 15 micrograms/L, and that a normal or high ferritin does not rule out iron deficiency because ferritin rises in inflammatory states.

Provenance

  • Attributed findings: the following rest on a cited source — the depression risk figures, the reproductive-transition vulnerability finding and the sleep-architecture finding, from the review cited in Sources; the treatment-efficacy quotation, from the 2022 position statement; and the ferritin advice, from the ACOG committee opinion. Everything else is general clinical description.
  • Route of retrieval: the source texts were obtained through search results rendering those documents, not by direct retrieval. Authorship of the sleep review was not confirmed from the retrieved text and is not stated.
  • General clinical content: everything other than those attributed findings is general clinical description rather than a retrieved guideline, and is written at that level of generality deliberately — the definitions and vocabulary, how the transition unfolds, the symptom pattern, the cognitive-symptom section, which tests earn a place, and the sections on work, family, wider care and unsettled questions.
  • Not asserted here: reference ranges, cut-offs and interpretation for the tests named above; contraceptive choices for individual risk profiles; and treatment regimens. The tests are named because knowing what to ask for is useful; what their results mean is a clinical judgement and is deliberately not given here.

Medical information notice: general educational information, not a substitute for individualized medical advice, diagnosis, or treatment.

Written by Kanwar Partap Singh Gill, MD, family medicine physician in Fresno, California ·